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ABSTRACT 
 
Xanthine oxidoreductase (XOR) is a complex 
molybdoflavoprotein that is the terminal 
enzyme of purine catabolism in man and 
higher apes. XOR has been extensively 
studied in a number of species, but human 
studies are few. Because of its metabolic 
position and the characteristics of the 5´-
regulatory region of its gene, and because it 
has been implicated in human pathology, we 
also hypothesized that the regulation of XOR 
expression in man is unique and cannot be 
extrapolated from animal studies. Since XOR 
is expressed in the normal and lactating 
mammary gland, and because animal studies 
have suggested an involvement of XOR in 
tumorigenesis, we hypothesized that XOR 
may be differentially expressed in cancerous 
human mammary epithelial cells. 
We purified the enzyme from human milk 
and produced anti-XOR antibodies in order 
to study the molecular forms, the ratio of 
XOR activity to protein, and the cellular 
localization of XOR in normal human 
tissues. The results showed that human XOR 
has a molecular size similar to other 
mammalian XOR enzymes. Most of the 
enzyme is in an inactive form in milk but not 
in liver and intestine, in which the 
relationship between XOR activity and 
protein is constant during ontogenesis. In 
normal human tissues studied, the protein is 
localized to periportal hepatocytes and 
epithelial cells of the mammary gland and 
intestine. The vascular endothelium of the 
intestine, mammary gland, and skeletal 
muscle also express XOR, whereas no cells 
in the heart, brain, or lung show 
immunoreactivity. 
Given that oxygen is a substrate of XOR and 
hypoxia has been shown to regulate XOR in 
cultured animal cells, we investigated the 
regulation of the protein in cultured human 
bronchial epithelial cells under different 
oxygen concentrations. XOR activity is 
increased in hypoxia with no change in XOR 
protein concentration, mRNA expression or 
promoter activity, whereas in hyperoxia the 
enzyme is inactivated with no change in 
protein or mRNA levels. Indirect evidence 
suggested that the mechanism of inactivation 
by oxygen, already under normal cell culture 
atmosphere, occurs at the molybdenum 
center of XOR, and that the inactivation is 
reversed in hypoxia, resulting in apparent 
induction of enzyme activity.  
Using tissue microarray samples from a large 
population-based cohort of breast cancer, 
with well-characterized clinicopathological 
parameters and outcome data, we 
demonstrated that XOR is downregulated in 
more than half of the breast tumors studied, 
and that absence of XOR is an independent 
predictor of unfavorable outcome. 
In conclusion, this series of studies clarified 
the distribution of XOR in normal human 
tissues and the mechanisms of regulation of 
the enzyme by oxygen, thus providing a 
better understanding of the physiological 
behavior of the enzyme. Moreover, the 
differential expression of XOR in breast 
cancer may have clinical implications as a 
novel prognostic marker. 
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REVIEW OF THE LITERATURE 
 
1. Pathways of human purine metabolism 
The major purine compounds in the cell are 
adenine and guanine ribo- and deoxyribo-
nucleotides and nucleic acids. They play an 
essential role in energy-requiring reactions, 
nucleic acid synthesis, and as signaling 
molecules.  
Net contributions to body pools of purine 
compounds are by synthesis of purine 
nucleotides from nonpurine precursors (de 
novo synthesis) or by dietary purine 
ingestion. Since the energy cost of 
synthesizing a purine nucleotide de novo is 
six times higher, in ATP equivalents, than 
that of reutilizing an intact purine ring, cells 
have efficient mechanisms for the salvage of 
degraded purines (Raivio et al., 2001). 
Hypoxanthine is quantitatively the most 
important purine catabolic product, 
since the breakdown pathways of adenine 
ribo- and deoxyribonucleotides converge to 
yield hypoxanthine. Its main metabolic fate is 
phosphoribosylation by hypoxanthine 
phosphoribosyltransferase (HPRT) to inosine 
monophosphate (IMP), i.e. the salvage 
pathway. Yet, in situations of increased 
nucleic acid or ATP degradation, the purine 
catabolic pathway is overloaded and 
degradation products accumulate (Raivio et 
al., 2001). 
Xanthine oxidoreductase (XOR) catalyzes 
the two last steps in the catabolic pathway in 
humans and higher apes, with uric acid as the 
end product of purine metabolism, whereas 
in all other animal species uric acid is further 
metabolized into allantoin by uricase. 
Guanine nucleotides are catabolized to 
guanine, which is a substrate of HPRT and 
can thus be reutilized, or it may be 
deaminated to xanthine and then oxidized by 
XOR to uric acid (Figure 1) 
De novo
synthesis
DNA/RNA
GTP/dGTP
AMP
HPRT
Salvage
pathway
GMP
ATP/dATP
IMP Inosine Hypoxanthine
XOR
XOR
Xanthine
Uric acid
Guanosine
Guanine
Adenosine HPRT
Figure 1. Pathways of human purine 
ribonucleotide metabolism. The reactions 
catalyzed by XOR and the purine salvage 
pathway are demonstrated. XOR, 
xanthine oxidoreductase; IMP, inosine 
monophosphate; HPRT, hypoxanthine 
phosphoribosyltransferase; dATP, deoxy 
ATP; dGTP, deoxy GTP. 
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2. Biochemistry of xanthine 
oxidoreductase 
2.1. Basic reactions catalyzed by XOR 
Xanthine oxidoreductase (XOR) oxidizes 
hypoxanthine to xanthine and xanthine to 
uric acid (Figure 2). The enzyme exists in 
two forms, xanthine dehydrogenase (XDH, 
EC 1.1.1.204) and xanthine oxidase (XO, EC 
1.1.3.22). Both enzymes can reduce 
molecular oxygen to superoxide anion and 
hydrogen peroxide, but the preferred electron 
acceptor is NAD+ for XDH and molecular 
oxygen for XO (Hille and Nishino, 1995). 
Other purine substrates of XOR include 
adenine (Krenitsky et al., 1986), a number of 
synthetic purine derivatives, e.g. 6-
mercaptopurine (Krenitsky et al., 1986), and 
allopurinol (Massey et al., 1970).  
The reactive oxygen species, which include 
superoxide and hydrogen peroxide, produced 
by XO react with and modify the structure 
and function of macromolecules including 
proteins, lipids, carbohydrates, and nucleic 
acids (Castro and Freeman, 2001). Reactive 
oxygen species can also serve as second 
messengers in signal transduction and 
participate in cellular functions such as 
cytokine and growth factor action, ion 
transport, and regulation of transcription 
(Lander, 1997). On the other hand, the 
primary product of XOR, uric acid, is an 
antioxidant and has been ascribed a 
protective role against free radical effects 
(Ames et al., 1981). 
2.2. Structure of XOR  protein 
XOR and aldehyde oxidase (AO) utilize a 
molybdenum cofactor and a flavin to oxidize 
their respective substrates, and these 
enzymes are the only members of the family 
of molybdoflavoproteins in mammals 
(Garattini et al., 2003). The two enzymes 
have remarkable similarities. They have a 
high level of amino acid identity, as well as 
similar molecular weights (Ichida et al., 
1993; Terao et al., 2000), and a high degree 
of conservation of the intron/exon junctions 
(Terao et al., 1998), suggesting a common 
evolutionary origin. 
The purified XOR is a homodimer, 
consisting of identical subunits of ~150 kDa 
each containing domains with molecular 
masses of 20, 40, and 85 kDa (Hille and 
Nishino, 1995). Each subunit includes one 
OH
XDH
OH OH
HO HO
OHNAD
+ NADH
O2 O-2, H2O2
NAD+ NADH
O2 O-2, H2O2
Hypoxanthine Xanthine Uric acidXOXO
XDH
Figure 2. Reactions catalyzed by the dehydrogenase (XDH) 
and oxidase (XO) forms of xanthine oxidoreductase. O2.-, superoxide;  
H2O2, hydrogen peroxide. 
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molybdopterin cofactor, two non-identical 
iron-sulfur (Fe/S) clusters, and one flavin 
adenine dinucleotide (FAD) center (Figure 
3), and the subunits are connected to each 
other with a linker peptide. The molybdenum 
in the molybdenum cofactor is covalently 
linked to two essential cysteins and to one 
essential sulfur atom (Enroth et al., 2000). 
The oxidation of hypoxanthine and xanthine 
takes place at the molybdopterin site, where 
the purine substrate is bound to the 
molybdenum and donates two electrons, 
reducing Mo (VI) to Mo (IV) (Hille and 
Nishino, 1995). The arrangements of the 
cofactors indicate that the Fe/S clusters 
provide an electron transfer pathway from 
the molybdopterin cofactor to FAD (Enroth 
et al., 2000; Hille and Nishino, 1995). In 
addition, it has been suggested that the Fe/S 
clusters have a role as an electron sink to 
provide electrons to the FAD cofactor 
(Nishino and Okamoto, 2000). Finally, the 
reduction of the co-substrates NAD+ or 
molecular oxygen occurs at the FAD site 
(Hille and Nishino, 1995) (Figure 3). 
2.3. Dehydrogenase to oxidase conversion  
XOR is synthesized as the dehydrogenase 
(XDH) form, which appears to be the 
predominant enzyme type in intact and 
freshly prepared mammalian tissue (Stirpe 
and Della Corte, 1969). However, the 
dehydrogenase (XDH) can be converted to 
the oxidase (XO), reversibly by sulfhydryl 
(SH) oxidation or irreversibly by proteolysis. 
Reversible XDH to XO conversion is due to 
SH-group oxidation of specific cysteine 
residues and generation of disulfide bridges 
(S-S), which can be reversed by SH-reducing 
agents, such as dithiothreitol (Nishino, 1997).  
Treatment of XOR by trypsin nicks isolated 
rat liver XOR into three fragments of 20, 40, 
and 85 kDa, but the peptide fragments are not 
dissociated and XOR activity is retained. The 
fragments are separated by electrophoresis 
under denaturing conditions (Amaya et al., 
1990). The crystal structure of bovine milk 
XOR has revealed that proteolytic cleavage 
of XDH leads to major structural alterations 
 
 
 
 
NADH
O-2, H2O2
NAD+
O2
Hypoxanthine
Xanthine
Xanthine
Urate
20 kDa
85 kDa
40 kDa
N-
C-
e-
2 Fe/S
FAD
Mo-pterin
Figure 3. Proposed domain structure of 
XOR. Oxidation of xanthine and 
hypoxanthine occurs at the 
molybdopterin site (Mo-pterin), and 
reduction of NAD+ or molecular oxygen 
takes place at the flavin adenine 
dinucleotide (FAD) site. The amino (N) 
and carboxy-terminal (C) ends of the 
protein are indicated. 
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around the FAD site and access of the NAD 
substrate to the FAD center is blocked 
(Enroth et al., 2000). By rapid purification, 
and the use of dithiothreitol, the enzyme 
from bovine milk remains in the XDH form 
(Hunt and Massey, 1992).  
2.4. The human XOR gene 
The human XOR gene was initially mapped 
to chromosome band 2p22 (Ichida et al., 
1993; Rytkonen et al., 1995), but was later 
assigned to band 2p23 (International Human 
Genome Sequencing Consortium 2001). The 
nucleotide sequence has an open reading 
frame of 3999 nucleotides, corresponding to 
1,332 amino acids. The primary structure of 
XOR is well conserved across the 
phylogenetic spectrum with high homology 
(~90 % identity) between human (Ichida et 
al., 1993; Saksela and Raivio, 1996), rat 
(Amaya et al., 1990), and mouse (Terao et 
al., 1992) enzymes. The human XOR gene 
spans at least 60 000 bp of DNA and is 
composed of 36 exons and 35 introns (Xu et 
al., 1996).   
In contrast to the respective genes 
themselves, the 5´-untranslated regions of the 
XOR gene in human (Xu et al., 1996), rat 
(Chow et al., 1994) and mouse (Cazzaniga et 
al., 1994) are remarkably different, indicating 
different transcriptional regulation. The 5´-
flanking region of the human XOR gene 
contains several consensus sequences 
relevant to inflammation. These include 
potential binding sites for interleukin-1 and -
6, nuclear factor-κB, tumor necrosis factor-α, 
and interferon-γ . Sequences for binding of 
transcription factors involved in 
developmental regulation have also been 
found, including activator protein-1 and -2, 
and homeobox promoter sites (Xu et al., 
1996). It has been shown that the promoter 
activity of the human XOR gene is repressed 
relative to the mouse gene. An E-box and a 
TATA-like element present in the human but 
not in the mouse promoter apparently are 
required for the control of human XOR 
promoter activity. Another difference is that 
the 5´-flanking region of the human XOR 
gene has a larger number of consensus 
sequences for potential promoter elements 
than do either the rat or the mouse (Xu et al., 
2000). In addition, the transcription factor 
nuclear factor-Y is important for activating 
the human XOR gene (Martelin et al., 2000).  
2.5. Inactivation of XOR 
Inhibitors of XOR can be divided into two 
categories; molecules which are structural 
analogs to purine substrates and molecules 
which are unrelated to physiologic substrates. 
Allopurinol and its major metabolite 
oxypurinol are purine analogs that form a 
tight-binding complex with molybdenum at 
the active site, leading to the inhibition of 
XOR (Massey et al., 1970). 
Inactive forms of XOR have been well 
documented. Loss of a sulfur atom from the 
active site results in inactivation of milk 
XOR (Nishino et al., 1983), and in rat liver in 
vivo, up to 50% of XOR has been shown to 
be inactive (Ikegami and Nishino, 1986). 
Cyanide is also capable of modifying the 
molybdopterin cofactor by removing the 
essential sulfur atom, thus inactivating the 
enzyme (Coughlan et al., 1980). This may 
also be the mechanism by which the enzyme 
is inactivated in hyperoxia by oxygen 
metabolites in vivo (Terada et al., 1988). 
Desulfo-XOR can be reactivated by 
reinsertion of the sulfur atom at the 
molybdenum site, which is catalyzed by a 
sulfurase present in human tissues (Ichida et 
al., 2001). Loss of a molybdenum atom or the 
pterin cofactor from the enzyme also results 
in inactivation of the enzyme (Ventom et al., 
1988).  
3. Expression of XOR in organs and cells 
The wealth of biochemical information on 
isolated XOR is in contrast to the lack of 
knowledge on the cellular localization and 
the physiological function of this enzyme, 
especially in humans. XOR activity has been 
detected in almost all species studied (Parks 
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and Granger, 1986). In mammals, the liver 
and intestine have the highest XOR activity 
of any tissue (Al-Khalidi and Chaglassian, 
1965). The liver is also a rich source of AO, 
whereas in the lung AO protein and mRNA 
are strongly expressed, while XOR 
expression is low. Conversely, the intestine is 
rich in XOR, while AO expression is low (Li 
Calzi et al., 1995; Saksela et al., 1998).  
Substantial differences in organ distribution 
of XOR activity exist between mammalian 
species, making it difficult to extrapolate 
animal study results to human. The 
discrepancies in XOR expression between 
species may be explained by significant 
differences in the promoter regions (Xu et al., 
1996) (Cazzaniga et al., 1994; Chow et al., 
1994), suggesting diverse transcriptional 
regulation. 
3.1. Non-human species 
In one previous study bovine hepatocytes and 
intestinal epithelial cells lacked demonstrable 
XOR protein, whereas mammary gland 
epithelial cells and capillary endothelial cells 
of a variety of tissues including the 
mammary gland, liver, lung, skeletal muscle, 
heart, and intestine showed XOR 
immunoreactivity (Jarasch et al., 1981). In 
contrast, several other studies have localized 
XOR in the hepatocytes, e.g. in rat (Ichikawa 
et al., 1992) and chicken liver (Hattori, 
1989). Data on XOR activity in the heart are 
also inconsistent, showing high XOR activity 
in the myocardium of the dog and rat 
(Chambers et al., 1985; de Jong et al., 1990), 
but low activity in the rabbit (Downey et al., 
1988). Serum of some animals contains low 
XOR activities, whereas rat and mouse serum 
are relatively rich in XOR activity (Parks and 
Granger, 1986).  
In the mouse, XOR mRNA is expressed in 
the mammary gland epithelium 
(McManaman et al., 2002), and in the liver, 
lung, and intestine (Kurosaki et al., 1995).  
By immunoelectron microscopy of rat 
hepatocytes the subcellular localization of 
XOR was shown to be solely cytosolic 
(Ichikawa et al., 1992). However, in another 
study, XOR activity was identified by 
electron microscopy in peroxisomes, rough 
endoplasmic reticulum, lysosomes, and 
endocytic vesicles of rat hepatocytes 
(Frederiks and Vreeling-Sindelarova, 2002). 
Thus, the subcellular localization of XOR 
still remains controversial.  
3.2. Human tissues 
In general, XOR activity in human tissues is 
10-100 times lower than in rodents, including 
rat and mice (Al-Khalidi and Chaglassian, 
1965; Krenitsky et al., 1974; Wajner and 
Harkness, 1989). In humans, relatively high 
XOR activities are clearly present in the 
liver, intestine, mammary gland and milk 
(Al-Khalidi and Chaglassian, 1965; Hellsten-
Westing, 1993; Kooij et al., 1992; Saksela et 
al., 1998) (Table 1). In contrast, data on XOR 
in serum, brain, and myocardium are 
conflicting, showing both measurable activity 
(Table 1) and lack of  activity (Vettenranta 
and Raivio, 1990) (Al-Khalidi and 
Chaglassian, 1965; Parks and Granger, 
1986). The subcellular localization of XOR 
in human is still unknown.  
3.3. XOR expression in cell lines 
Several non-human cell lines such as those 
originating from bovine (Terada et al., 
1992b) and rat (Hassoun et al., 1994) 
endothelium, as well as mouse mammary 
epithelium (McManaman et al., 2000) show 
measurable XOR activity. Cultured human 
cells generally do not express XOR when 
cultured in normoxia (21% O2) (unpublished 
data from our laboratory). However, an SV-
40 immortalized human mammary epithelial 
cell line (HB4a) (Page et al., 1998) as well as 
isolated human aortic endothelial cells 
(Zweier et al., 1994) showed measurable 
XOR activity. 
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Table 1. Positive findings of XOR activity, protein, and mRNA in human. 
XOR Reference 
Activity Protein mRNA  
Intestine, 
liver, lung 
- Liver, 
intestine, lung, 
kidney, heart, 
brain 
(Saksela et al., 
1998) 
- - Liver, intestine (Wright et al., 1995) 
Liver, intestine - - (Vettenranta and 
Raivio, 1990) 
Liver, kidney, 
heart, brain 
- - (Wajner and 
Harkness, 1989) 
Liver, skeletal 
muscle, milk 
Cardiac- and skeletal muscle 
cells, capillary endothelial cells of 
cardiac- and skeletal muscle, 
mast cells, macrophages 
- (Hellsten-Westing, 
1993) 
Liver 
(periportal and 
pericentral 
hepatocytes), 
enterocytes 
and goblet 
cells in 
jejunum 
- - (Kooij et al., 1992) 
- Liver hepatocytes, bile duct 
epithelial cells 
- (Martin et al., 2004) 
- Liver hepatocytes and sinusoidal 
lining cells, mucosal cells of 
duodenum, arterial endothelial 
cells of duodenum heart, kidney, 
brain, and lung 
- (Moriwaki et al., 
1993) 
Milk -  (Page et al., 1998) 
- Mammary gland epithelial cells - (Cook et al., 1997) 
- Perinuclear and surfaces that 
appose neighboring cells of 
mammary gland epithelial cells 
(HB4a), and HUVEC in culture 
- (Rouquette et al., 
1998) 
- Myocytes in myometrium, villous 
stromal cells of the placenta, fetal 
membranes 
- (Telfer et al., 1997) 
- Serum - (Adachi et al., 1993; 
Battelli et al., 1999; 
Pesonen et al., 
1998) 
Heart - - (de Jong et al., 
1990; Eddy et al., 
1987) 
-, not analyzed; HUVEC, human umbilical vein endothelial cells; RT-PCR, reverse 
transcriptase-PCR. 
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4. Regulation of XOR  
Despite the biochemical function of XOR as 
a housekeeping enzyme in the catabolism of 
purines, its activity can be regulated by a 
variety of stimuli. 
4.1.  Inflammatory mediators 
Inflammatory mediators, particularly 
interferons, induce XOR in experimental 
models. Interferon-α and interferon inducers, 
such as lipopolysaccaride, increase XOR 
activity and mRNA concentrations in vivo in 
various mouse tissues (Kurosaki et al., 1995; 
Terao et al., 1992). Furthermore, XOR 
mRNA increases in vitro in mouse 
fibroblasts after treatment with interferon-
α and-γ (Falciani et al., 1992), and XOR 
activity is enhanced in rat pulmonary 
endothelial cells after culturing with 
interferon-γ (Dupont et al., 1992). Cytokines 
such as tumor necrosis factor-α, interleukin-
1, and interleukin-6, enhance XOR activity 
and gene expression in bovine renal 
epithelial cells (Pfeffer et al., 1994). 
Furthermore, it was shown by DNA 
microarray analysis of gene expression that 
the XOR gene is upregulated in a rat model 
of systemic inflammation (Chinnaiyan et al., 
2001), thus supporting a role for XOR in the 
inflammatory process.  
4.2. Lactation 
The mammary gland represents a good 
example of tissue- and stage-dependent 
expression of XOR. Under normal non-
lactating conditions, low levels of XOR 
mRNA, protein and activity are associated 
with the epithelium in the mouse mammary 
gland (Kurosaki et al., 1996). During the 
final phase of pregnancy and the whole 
period of lactation, there is a striking increase 
in XOR activity and the corresponding 
transcript (Kurosaki et al., 1996; 
McManaman et al., 2000). At the beginning 
of lactation, XOR is delocalized from the 
cytoplasm to the apical membranes of the 
mouse mammary gland epithelial cells, in 
which the protein is associated with milk fat 
globule proteins (McManaman et al., 2002). 
In the only human study using mammary 
epithelial cells, XOR activity and mRNA 
expression were increased after stimulation 
with tumor necrosis factor-α, interleukin-1, 
and interferon-γ (Page et al., 1998).  
Interestingly, mice heterozygous for a loss of 
function in the XOR gene (XOR+/-) are 
unable to maintain lactation because of 
membrane defects in the milk fat droplets 
and disruption of the mammary epithelial 
cells (Vorbach et al., 2002), indicating that 
XOR may have a structural role in the 
development of the mammary gland.   
Corticosteroids such as dexamethasone or 
cortisone transcriptionally induce XOR in 
mouse mammary gland cells, and the effect 
is further enhanced by prolactin (Kurosaki et 
al., 1996; McManaman et al., 2000).  
4.3. Oxygen 
4.3.1. Tissue oxygen concentration  
Hypoxia refers to below-normal levels of 
oxygen in air, blood, or tissue. Although cells 
are usually cultured in the laboratory at an 
ambient oxygen concentration of 21%, cells 
in the human body are generally exposed to 
much lower oxygen. Expressed in similar 
terms, the measured oxygen concentrations 
in vivo would be 4% for the liver (Wolfle et 
al., 1983), 3% for the renal cortex (Epstein et 
al., 1994), and as low as 2% for the 
myocardium (Rumsey et al., 1994). It has 
been shown that lowering the oxygen 
concentration of the culture media has 
beneficial effects on cultured cells, 
increasing the life-span and division rate of 
human fibroblasts (Packer and Fuehr, 1977; 
Storch and Talley, 1988). 
4.3.2. Oxygen sensing  
Even a small reduction in cellular oxygen 
concentration results in the activation of 
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oxygen-responsive genes. It has been 
suggested that an oxygen sensing mechanism 
exists in every mammalian cell, but no 
consensus regarding the nature of this sensor 
exists.   
Hydroxylation of hypoxia-inducible factor-1 
(HIF-1) is mediated by a group of HIF-1-
specific hydroxylases, and cobalt can 
inactivate the enzymes by occupying an iron-
binding site on the hydroxylases. Because 
proline hydroxylation requires molecular 
oxygen, it has been suggested that HIF-1-
specific hydroxylases are themselves the 
“oxygen sensors” (Semenza, 2004).  
Other data suggest that the oxygen sensor is a 
heme protein which undergoes allosteric 
modification in response to oxygen binding 
or release (Goldberg et al., 1988). Yet, other 
studies propose that mitochondria function as 
oxygen sensors by paradoxically increasing 
their generation of superoxide during cellular 
hypoxia (Chandel and Schumacker, 2000). 
4.3.3. Transcriptional and post-
transcriptional regulation by oxygen 
In mammalian cells, HIF-1 has emerged as a 
key regulator of oxygen homeostasis, playing 
a central role in responses to hypoxia. HIF-1 
is a transcription factor that targets genes 
involved in such diverse functions as 
angiogenesis, hormonal regulation, energy 
metabolism, cellular transport, growth, and 
apoptosis. The HIF-1 protein consists of α- 
and β-subunits. The cells maintain relatively 
stable concentrations of the HIF-1β-subunit, 
whereas HIF-1α concentrations vary, going 
up when oxygen levels are low and down 
when they are normal. It has been proposed 
that oxygen sensing and signaling occur via a 
common pathway, leading to the binding of 
HIF-1 to the consensus HIF-1 DNA binding 
site present in the hypoxia-responsive 
elements of oxygen responsive genes, 
leading to increased transcription (Schofield 
and Ratcliffe, 2004).  
Other than HIF-mediated responses to 
oxygen, particularly to reactive oxygen 
species, have been implicated. These include 
the activation of transcription factors such as 
nuclear factor-κB and activator protein-1, 
enhancing gene expression of pro-
inflammatory mediators (Rahman and 
MacNee, 1998). Post-transcriptional 
responses to oxidative stress are exemplified 
by heat shock protein Hsp33, which is under 
oxidative stress control through the formation 
of disulfide bonds (Graf and Jakob, 2002), 
and VEGF mRNA, which is stabilized in 
hypoxia (Claffey et al., 1998).  
4.3.4. Regulation of XOR by hypoxia and 
hyperoxia 
Oxygen tension is a significant determinant 
of XOR expression. In general, hypoxia 
tends to increase XOR, while hyperoxia 
decreases the activity of the protein. The 
regulation of XOR by oxygen has mostly 
been studied in animal-derived cells.  
Hypoxia. Data on the effects of hypoxia on 
XOR expression are conflicting, showing 
both transcriptional and post-translational 
regulation (Table 2). Elevated XOR activity 
has been documented in a number of studies 
on anoxic or hypoxic rat, bovine, or mouse 
endothelial cells (Hassoun et al., 1994; 
Kayyali et al., 2001; Poss et al., 1996; Terada 
et al., 1992b), as well as on human umbilical 
vein endothelial cells (Terada et al., 1992b). 
XOR activity and mRNA levels are increased 
in hypoxic rat endothelial cells (Hassoun et 
al., 1994) and in mouse fibroblasts (Terada et 
al., 1992b), supporting a role for 
transcriptional regulation. A putative binding 
site for HIF-1 has been identified in the 5´-
upstream region of the human XOR gene 
(Hoidal et al., 1997), but evidence of HIF-
mediated regulation of XOR has not been 
published. 
In contrast, post-translational regulation of 
XOR in hypoxia was suggested in bovine 
endothelial cells, since XOR activity 
increased, whereas XOR mRNA levels 
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remained unchanged (Poss et al., 1996). 
Another potential mechanism for post-
translational activation of XOR in hypoxic 
rat endothelial cells is the phosphorylation of 
the protein by casein kinase II (involved in 
cell growth) and p38 (involved in stress 
activation) (Kayyali et al., 2001).  
Hyperoxia. From the literature it seems that 
high oxygen concentrations regulate XOR at 
several levels, i.e. by post-translational 
inactivation of the enzyme or through 
transcriptional events. For example, in rat 
endothelial cells, XOR mRNA con- 
centrations were diminished after incubation 
in hyperoxia, as compared to normoxic cells 
(Hassoun et al., 1994) (Lanzillo et al., 1996). 
Conversely, XOR mRNA concentrations 
were not decreased in hyperoxic mouse 
fibroblasts, although there was a profound 
decrease in XOR activity (Terada et al., 
1997). Increasing concentrations of reactive 
oxygen species progressively decrease the 
activity of purified bovine XOR (Terada et 
al., 1991), and hyperoxia as well as reactive 
oxygen species inactivate the enzyme in 
isolated rat lungs and endothelial cells 
(Terada et al., 1988). 
 
 
 
Table 2. Effect of hypoxia on XOR in cultured cells. 
Oxygen Cell line XOR Reference 
(%)  Activity Protein mRNA  
0 Bovine EC ↑ ↔ ↔ (Poss et al., 1996) 
0 Mouse fibroblasts  
HUVEC 
Bovine lung EC 
Human intestinal  
↑ 
↑ 
↑ 
↑ 
↑ 
- 
- 
- 
↑ 
- 
- 
- 
(Terada et al., 1997) 
1 Bovine lung EC - - ↑ (Partridge et al., 
1992) 
3 
 
HUVEC 
Bovine BASMC 
Rat lung EC 
Rat fat pad EC 
↔ 
↑ 
↑ 
↑ 
- 
- 
- 
- 
- 
- 
- 
↑ 
(Hassoun et al., 
1994) 
3 Rat lung EC - - ↑ (Lanzillo et al., 
1996) 
3 Rat lung EC ↑ - - (Kayyali et al., 
2001) 
0-10 Bovine lung EC ↑ - - (Terada et al., 
1992b) 
-, not analyzed; ↔, no change; ↑, increased; ↓, decreased; EC, endothelial cells, HUVEC, 
human umbilical vein endothelial cells; BASMC, bovine aortic smooth muscle cells. 
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5. Role of XOR in human pathophysiology  
5.1. Genetic deficiency of XOR 
Inherited XOR deficiency is classified into: 
1. classical xanthinuria type I, lacking only 
XOR; 2. classical xanthinuria type II, lacking 
XOR and AO activity; 3. molybdenum 
cofactor deficiency, lacking XOR, AO, and 
sulfite oxidase. Most affected individuals 
with xanthinuria type I and II have no 
symptoms, but some patients may develop 
urinary tract calculi, acute renal failure, or 
myositis due to accumulation of insoluble 
xanthine (Raivio et al., 2001). Type I 
xanthinuria is a rare autosomal recessive 
disorder and a single-nucleotide mutation has 
been shown to be responsible for the disease 
(Ichida et al., 1997). A molybdenum cofactor 
sulfurase is responsible for inserting the 
essential sulfur atom into the molybdenum 
cofactor of XOR and AO, and a mutation of 
this sulfurase is apparently responsible for at 
least some cases of type II xanthinuria 
(Ichida et al., 2001). Recently, the generation 
of XOR knockout mice was reported, but a 
homozygous deletion of the XOR gene turned 
out to be lethal in the embryonic stage 
(Vorbach et al., 2002). This is in apparent 
contrast to human xanthinuria, since these 
patients do not seem to have a shortened life-
span. In contrast to xanthinuria type I and II, 
molybdenum cofactor deficiency is 
associated with severe neurological 
disorders, apparently due to concomitant lack 
of sulfite oxidase (Raivio et al., 2001).  
5.2. Ischemia-reperfusion  
XOR has been linked to the pathophysiology 
of reoxygenation after hypoxia, i.e. ischemia-
reperfusion (I/R) injury (McCord, 1985). 
Examples of such clinical situations include 
myocardial infarction, stroke, and organ 
transplantation. According to the hypothesis, 
a large amount of hypoxanthine is released 
during ischemia due to the depletion of ATP 
(Saugstad, 1975). Concurrently, XOR is 
converted from the XDH to the oxygen 
radical producing XO form. Upon 
reperfusion, when oxygen is reintroduced, 
XO oxidizes the accumulated hypoxanthine 
to produce toxic oxygen radicals that cause 
tissue damage (McCord, 1985). Initial 
evidence supporting this role for XOR in I/R 
injury was primarily indirect, based on the 
observation that allopurinol or oxypurinol, 
inhibitors of XOR, diminished cellular 
damage after reperfusion in the intestine 
(Granger et al., 1981; Parks et al., 1982). The 
time course for the dehydrogenase to oxidase 
conversion during ischemia varies depending 
on the animal model, organ, and cell type. 
For example, the conversion is rapid in 
isolated rat Kupffer cells and slow in aortic 
endothelial cells (Wiezorek et al., 1994).  
The main problem is whether XOR actually 
exists in the human organs that may suffer 
reperfusion injury, particularly the heart and 
brain, and whether the dehydrogense (XDH) 
form of the enzyme in fact is converted to the 
reactive oxygen species forming oxidase 
(XO) under these circumstances. Thus, 
although the proposed role for XOR in the 
pathogenesis I/R injury is attractive, it seems 
that conclusive evidence to support the 
hypothesis has not been presented. 
5.3. Cancer 
5.3.1. XOR and cancer 
Although XOR activity has been determined 
in a number of animal tumors and in a few 
human tumors (Table 3), little is known 
about the expression of XOR in cancer. XOR 
activity is significantly reduced in rat 
hepatomas (Ikegami et al., 1986), including 
the slowest growing and well differentiated 
tumors (Prajda and Weber, 1975). Mouse 
mammary tumors (Lewin et al., 1957) and 
colon carcinomas (Weber et al., 1978) show 
considerably decreased XOR activities 
compared to analogous normal tissue. In 
addition, XOR activity is decreased in human 
hepatocellular (Stirpe et al., 2002) and renal 
cell carcinoma (Durak et al., 1997), as 
compared to corresponding normal tissue. In 
a rat model for chemically induced mammary 
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gland carcinoma, using large-scale gene 
expression profiling by cDNA microarrays, 
the XOR gene was down-regulated compared 
to the normal and lactating gland (Shan et al., 
2002).  
The expression of XOR in human cancer has 
previously been examined only in one study 
involving breast cancer (Cook et al., 1997). 
This study included samples of normal breast 
(n = 6), ductal carcinoma in situ (n = 5), and 
infiltrating ductal carcinoma (n = 4). The 
results showed that no immunohistochemi- 
cally detectable XOR was observed in any of 
the intraductal in situ carcinomas or invasive 
breast carcinomas studied.  
Taken together, XOR is downregulated in 
cancerous tissue in virtually all rodent and 
human tumors studied. Interestingly, 
enzymes involved in the purine synthetic 
pathway were upregulated in tumors which 
showed decreased XOR activity as compared 
to corresponding normal tissue (Prajda et al., 
1976; Prajda and Weber, 1975), indicating an 
altered balance between purine catabolic and 
anabolic pathways.  
 
 
 
 
Table 3. XOR activity, protein and gene expression in rodent (rat or mouse) and 
human tumors. 
Origin XOR Reference 
 Activity Protein Gene  
Rodents     
  Mammary ca  ↓ - - (Lewin et al., 1957) 
  Mammary ca - - ↓ (Shan et al., 2002) 
  Hepatoma ↓ - - (Prajda and Weber, 
1975) 
  Hepatoma ↓ - - (Ikegami et al., 1986) 
  Colon ca ↓ - - (Weber et al., 1978) 
  Renal ca ↓ - - (Prajda et al., 1981) 
Humans     
  Mammary ca - ↓ - (Cook et al., 1997) 
  Hepatoma  ↓ - - (Stirpe et al., 2002) 
  Renal ca ↓ - - (Prajda et al., 1981) 
  Renal ca ↓ - - (Durak et al., 1997) 
  Prostate ca ↔ - - (Biri et al., 1999) 
  Head and neck ca - - ↑ (Belbin et al., 2002) 
-, not analyzed; ↔, no change; ↑, increased; ↓, decreased; ca, carcinoma 
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5.3.2. Prognostic and predictive markers 
for breast cancer 
Breast cancer is the most common malignant 
disease in women (Parkin et al., 1999). In 
2002, the age-adjusted incidence rate of 
breast cancer in Finland was 85 cases per 
100.000 females and a total of 3760 women 
were diagnosed with the disease (Finnish 
Cancer Registry, 2004). Breast cancer is a 
heterogenous disease, with marked variations 
in malignant potential and metastatic 
capacity (Donegan and Spratt, 2002). The 
risk of dying from breast cancer varies 
considerably between patients, from almost 
no risk for patients with in situ cancer 
(Warnberg et al., 1999) to 70% or more risk 
for relapse within five years from diagnosis 
in patients with poorly differentiated tumors, 
e.g. >10 positive lymph nodes, and tumor 
size >5 cm (National Cancer Institute, 
released April 2003, based on the November 
2002 submission). 
Axillary lymph node status and tumor size 
are the most powerful predictors of disease-
free survival in breast cancer (Goldhirsch et 
al., 2003), and histopathological grade adds 
independent prognostic information (Elston 
and Ellis, 1991). Estrogen and progesterone 
receptor status of the breast tumors are 
established biomarkers, mainly used as 
predictive factors for response to therapeutic 
and adjuvant hormone treatment (Fitzgibbons 
et al., 2000). Determination of human 
epidermal growth factor-2 (Her-2, ERBB2) 
overexpression or gene amplification is 
recommended to identify patients who may 
benefit from therapy with monoclonal 
antibodies (Trastuzumab) against the 
receptor (Bast et al., 2001). Although 
alterations in the tumor suppressor gene P53, 
and proliferation associated Ki-67 protein 
expression have been associated with poor 
prognosis in breast cancer, there is no 
consensus that testing should be performed in 
routine practice (Fitzgibbons et al., 2000). 
Numerous other biomarkers have been 
evaluated as potential prognostic factors in 
breast cancer (Hayes et al., 1996), and novel 
approaches to estimation of prognosis and 
prediction of therapeutic response include 
large-scale gene expression profiling (Sorlie 
et al., 2003; van 't Veer et al., 2002) 
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AIMS OF THE STUDY  
 
 
We hypothesized that because of its unique metabolic role and the structural characteristics of 
the promoter of its gene, the regulation of the expression of human XOR and its 
pathophysiological role are specific to humans and cannot be extrapolated from animal 
experiments. We were also interested in the relationship of XOR expression to breast cancer, 
given the inducibility of the enzyme during lactation and its low or absent expression in 
several tumors. Therefore, the aims of the study were: 
 
 
1. to characterize the molecular forms and activity to protein relationships of XOR in 
human liver and intestine,  
 
2.  to document the cellular localization of XOR in normal human tissues,  
 
3.  to evaluate the effect of oxygen on XOR activity, protein, mRNA, and promoter activity 
in cultured human epithelial cells,  
 
4.  to investigate the expression of XOR in malignant breast epithelial cells in a large cohort 
of human breast cancer, and to assess its potential prognostic value.  
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MATERIALS AND METHODS 
 
1. Patients and samples 
1.1. Human tissue specimens and serum 
samples (I, II) 
Samples of fetal liver and intestine were 
obtained from elective terminations (10-21 
weeks gestation), and neonatal samples (25-
35 weeks gestation) were from autopsies 
performed within two hours after death. The 
study protocol was approved by the Ethical 
Committees of the Hospital for Children and 
Adolescents, and the Department of 
Obstetrics and Gynecology, University of 
Helsinki, Helsinki, Finland. 
Adult liver tissue was obtained from the extra 
tissue at partial liver transplantation, and 
serum samples were from healthy adults and 
newborn infants (I).  
For the localization of XOR in healthy 
human tissues the samples were from: 1. the 
healthy margins of surgical specimens from 
liver, breast, kidney, and cerebral cortex; 2. 
transcutaneus biopsies of liver and breast; 3. 
hearts explanted from patients with 
hyperthrophic cardiomyopathy undergoing 
cardiac transplantation (II). The criterion for 
inclusion in the study was that the tissue was 
found to be normal upon histologic 
examination by a trained pathologist.  
1.2. Patients, exclusion criteria, and follow-
up (IV) 
To study the expression of XOR in breast 
cancer, five well-defined geographical 
regions comprising about 50% of the Finnish 
population were selected. Women diagnosed 
with breast cancer within these regions in 
1991 or 1992 were identified from the files 
of the Finnish Cancer Registry. A computer 
search recognized 2930 women, which 
constituted 53% of all breast cancers 
diagnosed in Finland within this time period.  
For inclusion in the study the following 
minimum information was required to be 
available: the date of diagnosis, age at 
diagnosis, history of other malignancies, 
postsurgical primary tumor size, axillary 
nodal status, follow-up data, and the vital 
status data at the end of follow-up.  
The total number of patients entered into the 
database was 2842. The following patients 
were excluded from the study: patients with 
lobular (n = 17) or ductal (n = 186) 
carcinoma in situ, those with distant 
metastases at diagnosis (n = 136), women 
with synchronous or metachronous bilateral 
breast cancer (n = 261) or history of other 
malignancy (except for basal cell carcinoma 
or cervical carcinoma in situ, n = 235), and 
women who did not undergo breast surgery 
(n = 42), leaving 1983 women with unilateral 
invasive breast carcinoma for the study. 
The median follow-up of patients alive at the 
end of follow-up is 9.5 years.  
1.3. Cell lines and culture (III) 
Transformed human bronchial epithelial cells 
(BEAS-2B) and human embryonic kidney 
cells (293T) were obtained from the 
American Type Culture Collection 
(Manassas, VA, USA) and Dr. Kalle Saksela 
(University of Tampere, Finland) 
respectively. BEAS-2B is a stable, SV-40 
transformed normal human bronchial 
epithelial cell line, which retains the ability 
to undergo squamous differentiation (Ke et 
al., 1988; Reddel et al., 1988). BEAS-2B 
cells were cultured in serum-free hormone-
supplemented bronchial epithelial cell 
growth medium (Cytotech ApS, Hellebaek, 
Denmark) at 37 °C in a 5% CO2 humidified 
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atmosphere. 293T cells were grown in 
Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco, Europe, Paisley, UK).  
For exposure of confluent cells to hypoxia 
(0.5 or 3% O2) or hyperoxia (95% O2), a 
preanalyzed gas mixture (5% CO2, specified 
O2 %, balance N2, AGA, Finland) was 
infused into airtight humidified chambers 
(Billups-Rothenburg, Del Mar, CA) in which 
the cells were grown. 
2. Methods 
2.1. Sample preparation 
2.1.1. Tissue samples (I, II, IV) 
Human tissue specimens were snap frozen in 
liquid nitrogen and stored at -70°C. Thawed 
samples were homogenized in 100 mM Tris-
HCl (pH 8.0) containing mercaptoethanol, 
and sonicated on ice. The sonicates were then 
centrifuged and the resulting supernatants 
were used for further analysis (I). 
For immunohistochemistry, fresh tissue 
specimens were immediately immersed in 
10% neutral buffered formalin and embedded 
in paraffin according to standard 
histopathological procedures (II, IV). 
2.1.2. Cultured cells (III) 
For enzyme activity measurements and 
Western blotting, cells were washed twice 
with PBS, mechanically harvested, and 
centrifuged. The cell pellets was resuspended 
in 50 mM potassium phosphate buffer, pH 
7.8, containing 0.5 mM dithiothreitol and 1 
mM EDTA, sonicated on ice, and 
centrifuged. 
For mRNA analysis, total RNA was 
extracted from BEAS-2B cells using the acid 
phenol-chlorophorm method (Chomczynski 
and Sacchi, 1987). 
2.2. Enzyme activity measurements (I, III) 
2.2.1. XOR activity (I, III) 
After electrophoresis of purified XOR 
preparations in 7.5% agarose gel under non-
denaturing conditions, XO activity was 
visualized by incubating the gel in 1.35 mM 
xanthine and 0.02% nitroblue tetrazolium 
diluted in 0.05 M phosphate buffer for 30 
min (I). 
The combined XDH and XO activities (I) 
from tissues were measured using 14C-
hypoxanthine as substrate, and the formation 
of 14C-xanthine and 14C-uric acid was 
followed by thin-layer chromatography. The 
spots containing hypoxanthine and xanthine 
plus uric acid were scraped off and counted 
using liquid scintillation (Vettenranta and 
Raivio, 1990).  
For XOR activity measurements (III), cell 
supernatants were incubated for 60 min in the 
presence of 14C-xanthine (0.1 mM, specific 
activity 58 mCi/mmol; NEN, Life Science 
Products Incorporation, Boston, MA). The 
combined XDH and XO activities were 
measured in the presence NAD+ (400 µM) 
and for XO activity NAD+ was omitted. The 
uric acid produced was separated by HPLC 
(Shimadzu, Kyoto, Japan) with a reverse-
phase column and eluted with 50 mM 
potassium phosphate, pH 4.5. Finally, 
radioactivity was quantified with a 
Radiomatic Flow Scintillation Analyzer 
(Packard Instrument, Meriden, CT, USA). 
XOR activity was expressed as nmol/min per 
mg total protein, which was analyzed using 
the Bio-Rad DC protein assay (Bio-Rad 
Laboratories, Hercules, CA, USA). 
Inactivation of XOR by hydrogen peroxide 
was studied by using purified bovine XOR 
(Biozyme Laboratories, South Wales,UK). 
XOR activity was determined 
spectrophotometrically at 295 nm, by 
following the production of uric acid over 3 
min before and after 30 min of incubation 
with H2O2 (III). 
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2.2.2. 2, 6-dichlorophenolindophenol 
reduction and NADH oxidation (III) 
Transfer of electrons from xanthine to the 
artificial electron acceptor 2, 6-
dichlorophenolindophenol (DCPIP) was 
measured spectrophotometrically by 
monitoring the absorbance of DCPIP at 600 
nm. The oxidation of NADH was monitored 
spectrophotometrically at 340 nm.  
2.3. Purification of XOR and production of 
anti-XOR antibodies (I) 
Buffered human breast milk was heated to 50
°C with Triton X-100, fractionated with 
ammonium sulfate between 20 and 70 g/l, the 
resulting pellet was resuspended in 5 mM 
phosphate, and dialyzed against the same 
buffer. The proteins were separated in a 
Diethylaminoethyl (DEAE)-Sepharose 
column and the enzyme was eluted with a 
linear gradient of 5-40 mM phosphate. The 
fractions containing the highest XOR 
activities were pooled, after which 20% 
hydroxyapatite was added, and the gel was 
eluted stepwise with phosphate. The eluates 
with the highest specific XOR activities were 
pooled and subjected to HPLC using a 
hydroxyapatite column. The purification was 
monitored by calculating absorbances at 280 
and 450 nm, by SDS-PAGE, and by 
measuring XOR activities.  
For production of XOR antiserum, three 
rabbits were immunized three times at 3-
week intervals with purified human milk 
XOR (50 µg). The rabbits were bled two 
weeks after the final immunization, and the 
antiserum was purified by solid phase 
absorption with the globulin fraction of 
human serum and with major milk proteins 
(β-caseins, β-lactoglobulin, and lactoferrin).  
2.4. ELISA (I, III) 
For ELISA measurements, microtiter plates 
were coated with the purified XOR antiserum 
over night and residual binding sites were 
blocked with 2% BSA-TBS. Plates coated 
with 2% BSA-TTBS were used as controls 
for non-specific binding. XOR standards (1-
50 ng/mg) and samples (diluted 1:5 or more) 
were diluted in 1% BSA-TTBS, and 
incubated over night at room temperature. 
After washing with TTBS, alkaline 
phosphatase conjugated anti-XOR antibodies 
(diluted 1:300) was added into the wells and 
incubated for 4 h. The substrate 
(paranitrophenylphosphate and 
diethanolamine) was added, and the plates 
were incubated for 45 min at 37°C. The 
absorbances were calculated at 405 nm by a 
Multiscan MS (Labsystems, Helsinki, 
Finland).  
2.5. Electrophoresis and Western blotting 
analysis (I, III) 
For Western analysis, the proteins were 
boiled in a buffer containing β-
mercaptoethanol (5 min at 95°C), and loaded 
onto a 7.5% SDS-polyacrylamide gel. After 
electrophoresis the proteins were transferred 
onto Immobilon-P membranes (Millipore, 
Bedford, MA). Nonspecific binding was 
blocked with bovine skimmed milk 2-5% 
(w/v) for 60 min, after which the membranes 
were incubated with the XOR antiserum 
diluted 1:200 (I) or 1:300 (III) for 2 h. The 
membranes were then  incubated with 
alkaline phosphatase–conjugated anti-rabbit 
antibody (diluted 1:100) (I) or with 
horseradish peroxidase-conjugated anti-
rabbit antibody (diluted 1:5000, Jackson-
Immuno Research Laboratories, West Grove, 
PA, USA) (III). For visualization, the 
membranes were incubated with the alkaline 
phosphatase substrate 5-bromo, 3-
inolylphosphate (BCIP)/nitrobluetetrazolium 
(NBT) (I) or by using enhanced 
chemiluminescence (Amersham Pharmacia 
Biotech, Buckinghamshire, UK) (III). 
2.6. Immunohistochemistry (II, IV) 
The sections (4 or 5µm) were deparaffinized 
and rehydrated, and endogenous peroxidase 
was quenched by incubation of slides in 0.3 
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(II) or 1% (IV) (v/w) hydrogen peroxide for 
30 or 10 min respectively.  
For localization of XOR in normal tissues 
(II), the sections were heated in 10 mM citric 
acid (pH 6.0) in a microwave oven for 10 
min to enhance antigen, and incubated with 
20% normal goat serum (Vectastain Elite 
ABC kit, Vector Laboratories, Burlingame, 
CA) to block nonspecific binding. The 
sections were then incubated with anti-XOR 
antibodies diluted 1:200 in PBS overnight at 
+4°C. Biotinylated goat anti-rabbit antibody 
(Vectastain Elite ABC kit) was added onto 
the sections for 1 h and then incubated with 
an avidin: biotinylated horseradish 
peroxidase complex (Vectastain Elite ABC 
kit). For visualization, 0.05% 3,3´-
diaminobenzidine (DAB) (Sigma Chemical 
Co., St. Louis, MO) was added onto sections.  
For detection of the XOR in normal and 
tumor tissue (IV), the slides were heated in 
Target Retrieval Solution, pH 6.0 (DAKO, 
Carpinteria, CA) at 95-97°C for 30 min. The 
sections were incubated with anti-XOR 
antibodies diluted 1:50 in Blocking Solution 
(Powervision, Immunovision, Inc., Daly 
City, CA) overnight at +4ºC. For detection, 
an antimouse-peroxidase polymer (dextran) 
and diaminobenzidine as a chromogen 
(Powervision) was added onto the sections. 
Finally, the slides were counterstained with 
hematoxylin diluted 1:10 and embedded.  
To exclude the possibility of non-specific 
reactions of secondary antibodies, control 
sections were processed without primary 
antiserum (II, IV). In addition, sections were 
stained with the preimmune serum from the 
immunized rabbit (II, IV), and also with the 
XOR antiserum after absorption with purified 
XOR (II). 
2.7. Preparation of tumor tissue array 
blocks and scoring of XOR staining 
(IV) 
Representative tumor regions in formalin-
fixed paraffin-embedded samples were first 
defined in hematoxylin-eosin-stained 
sections and marked. Tumor tissue array 
blocks were then produced by punching a 0.6 
mm tissue cylinder through a histologically 
representative area of each “donor” tumor 
block, which was then inserted into an empty 
“recipient” tissue array paraffin block using a 
specific instrument (Kononen et al., 1998). 
From the tumor samples available 19 tissue 
array blocks were prepared, each containing 
50 to 144 tumor samples.  
Evaluation of the tissue array slides was 
aided by the use of a computer-controlled 
and motorized specimen stage (EcoDrive, 
Märzhauser Inc., Germany) installed on a 
light microscope (Olympus BX50). XOR 
staining of the cytoplasm and nucleus were 
scored separately. Cytoplasmic XOR 
expression was scored as follows: strong 
staining intensity comparable to that of 
normal breast epithelial cells; clearly 
decreased staining intensity as compared to 
that of the normal breast epithelium; 
negative, no visible staining for the XOR in 
more than 90% of the cancer cells.  
Nuclear XOR staining intensity was 
compared to that of nuclei in normal breast 
cells and scored as follows: strong staining; 
moderate staining; and no visible staining. 
Strong and moderate staining of the nuclei 
represents increased XOR expression as 
compared to the nuclei of the normal breast 
epithelial cells. 
2.8. Ribonuclease protection assay (III) 
Ribonuclease protection assay (RPA) was 
performed using a commercially available kit 
according to the manufacturer’s 
recommendations (RPA II kit; Ambion, 
Austin, TX, USA), using 20 µg of total 
cellular RNA. The XOR antisense riboprobe, 
corresponding to the nucleotides 405-789 of 
the human XOR cDNA, was P32-labeled. To 
normalize for RNA content, the samples 
were hybridized with RNA probes 
transcribed from human β-actin cDNA. 
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2.9. Assessment of cell injury (III) 
The cell suspension was incubated in 0.4% 
trypan blue for 5 min, and counted in a 
Bürker cell counting chamber. Trypan blue-
negative cells were considered viable. 
2.10. Promoter constructs and reporter gene 
analysis (III) 
For studying the response of the XOR 
promoter to hypoxia, 293T cells were 
transfected with human XOR promoter 
fragments and with a hypoxia-responsive 
reporter gene construct (HRE-luc) carrying 
three tandem copies of the erythropoietin 
hypoxia-responsive element coupled to 
luciferase (kindly provided by Dr. Pekka 
Kallio) as previously described (Martelin et 
al., 2000). The transfections were carried out 
using the FuGene6 transfection reagent 
(Roche Molecular Biochemicals, 
Indianapolis, IN), and transfection efficiency 
was controlled for by cotransfection with a β-
galactosidase-carrying construct (pCMVβ, 
Clontech, Palo Alto, CA). After transfection 
the cells were exposed to either 0.5 or 21% 
oxygen for 24 h. Luciferase and β-
galactosidase were then measured (Martelin 
et al., 2000). 
2.11. Statistics (I, III, IV) 
Pearson´s product-moment correlation was 
used to estimate the relationship between two 
continuous variables identified as XOR 
activity and protein concentration (I).  
Enzyme activities before (control) and after 
exposures were compared using the unpaired 
Student´s t-test. The values are shown as 
means ± SD (III).  
Associations between XOR expression and 
clinicopathological parameters were analyzed 
using the chi-square test, and life-tables were 
calculated according to the Kaplan-Meier 
method. Distant disease-free survival 
(DDFS) was calculated from the date of the 
diagnosis to the first detection of metastases 
outside the locoregional area, or death from 
breast cancer. The logrank test was used to 
calculate the statistical significance of the 
difference in recurrence-free survival 
between two groups, and the logrank test for 
trend in case of three or more categories. 
Multivariate survival analysis was calculated 
using the Cox proportional hazards model 
(IV). P-values were two-tailed and values 
<0.05 were considered significant. 
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RESULTS 
 
1. Organ distribution and molecular 
forms of human XOR (I) 
1.1. The purified XOR preparation and 
anti-XOR antibodies 
To produce polyclonal anti-XOR antibodies, 
we purified XOR from human milk, and the 
protein was eluted from a DEAE-Sepharose 
column as a single peak.  
The purified XOR preparation was analyzed 
with electrophoresis under non-denaturing 
conditions, and one band with a molecular 
size of 300 kDa was observed. The XOR 
activity band corresponded to this band, 
which was partially sequenced and the 
amino acid sequence corresponded to the 
human XOR sequence deduced from the 
known cDNA structure. When subjected to 
an SDS-PAGE analysis the purified XOR 
preparation showed a main band of 143 kDa, 
with additional bands of 125, 87, and 59 
kDa (I, Figure 2).  
After absorption of the anti-XOR antiserum, 
produced in rabbits, with the globulin 
fraction of human serum and lactoferrin, the 
antiserum gave one major band in Western 
analysis with the purified XDH/XO 
preparation and human milk, with an 
estimated molecular weight of 143 kDa and 
additional minor bands of 125, 87 and 59 
kDa (I, Figure 3). The bands corresponded 
well with the protein bands in SDS-PAGE 
(I, Figure 2). Lactoferrin, α- and β-caseins, 
β-lactoglobulin, and normal human serum (I, 
Figure 3) were negative upon Western 
blotting. 
1.2. XOR protein in tissue homogenates 
The anti-XOR antibodies recognized bands 
of similar size in Western blots of the 
purified preparation and human milk (I, 
Figure 3). In fresh liver homogenates treated 
with antiproteases, the three largest bands 
were observed, in the intestine only the two 
largest (I, Figure 4). Brain, heart, skeletal 
muscle, and serum did not show 
immunoreactivity, whereas lung and kidney 
showed one faint band of 143 kDa in some 
samples (I, Figure 4) After trypsin treatment 
of liver homogenate and the purified XOR 
preparation, the main 143 and 125 kDa bands 
disappeared and the 87 kDa band became 
more intense (I, Figure 6). The same pattern 
was seen after incubation of liver 
homogenate with protease inhibitors at 37°C 
for 20 min.  
1.3. XOR activity to XOR protein 
relationship  
By ELISA, XOR concentrations were 146 ± 
70 ng/mg total protein (mean ± SD) for the 
liver and 556 ± 320 ng/mg total protein for 
the intestine. Lung and kidney had clearly 
smaller although measurable amounts of 
XOR (40-80 ng/mg total protein), whereas 
the XOR protein concentrations in brain, 
heart, skeletal muscle, and serum were below 
the detection limit. When XOR activities for 
the intestine and liver were compared with 
XOR protein concentrations in each of the 
samples, a linear correlation was found in 
both of the organs, r = 0.76 for the liver and r 
= 0.91 for the intestine (I, Figure 5). The 
specific activities were approximately 3 
µmol/min/mg XOR protein for both organs, 
whereas the specific activity for human milk 
was only 20% of that in the liver and 
intestine. 
2. Localization of human XOR in normal 
human tissues (II) 
Using polyclonal anti-XOR antibodies raised 
against human milk XOR (I), the protein was 
localized in normal human tissues (Table 4). 
Strong staining of XOR was seen in the 
epithelial cells of the lactating mammary 
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gland and the proximal intestine (II, Figure 
1). Also the periportal hepatocytes as well as 
the Kupffer cells of the liver showed intense 
staining. Moderate XOR expression was 
observed in the epithelial cells of the non-
lactating mammary gland and in the 
pericentral hepatocytes, whereas pericentral 
Kupffer cells did not show XOR 
immunoreactivity (Figure 4). The cytoplasm  
of the capillary endothelial cells in the non-
lactating and lactating mammary gland, 
proximal intestine, skeletal muscle, and 
kidney showed moderate XOR expression. In 
addition, the arterioles of the mammary gland 
showed XOR immunoreactivity (II, Figure 
2). All cells in the heart, brain, and lungs 
were below the detection limit (II, Figure 1).
 
 
 
Table 4. Localization and staining intensity of XOR in normal human tissues (II, IV). 
Tissue XOR Localization 
Non-lactating mammary 
gland 
Acinar cells of terminal ducts (+) and large ducts (+), 
capillary endothelial cells (+) and arterioles (+), 
myoepithelial cells (-) 
Lactating mammary gland Epithelial cells of all ducts (++), endothelial cells of 
capillaries (+) and arterioles (+), myoepithelial cells (-) 
Liver Periportal hepatocytes and Kupffer cells (++), 
pericentral hepatocytes (+), portal vein endothelium (-), 
hepatic artery endothelium (-)  
Proximal intestine 
  
Enterocytes and goblet cells (++), capillary endothelial 
cells (+) 
Skeletal muscle Muscle cells (-), endothelial cells of capillaries and 
venules (+) 
Kidney Capillary endothelial cells in connective tissue (+), 
tubules and glomeruli (-) 
Heart (-) 
Brain (-) 
Lung (-) 
Strong (++), moderate (+), and no (-) staining of XOR. 
 
A B C D
Figure 4. Immunohistochemical localization of XOR in normal human liver (A), 
proximal intestine (B), and lactating breast (C). An arteriole from lactating breast 
is positively stained (D). 
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3. Regulation of XOR by oxygen (III) 
3.1. Post-translational regulation of XOR in 
hypoxia and hyperoxia  
XOR activity in BEAS-2B cells grown in 
hypoxia (0.5 and 3% O2) was three- to 
eightfold higher respectively, compared to 
cells grown in normoxia (21% O2) (III, 
Figure 1), whereas XOR concentrations and 
mRNA levels were unaltered (III, Figure 3). 
Incubation of cells with cobalt chloride did 
not alter XOR activity. The XOR promoter 
activity remained unchanged in hypoxic as 
compared to normoxic cells (III, Figure 2). 
Hyperoxia (95% O2) abolished cellular XOR 
activity, whereas XOR concentrations did not 
change as compared to normoxia (III, Figure 
5). Reoxygenation of cells after incubation in 
hypoxia returned XOR activity to basal 
levels (III, Figure 4).  
The oxidase form of the enzyme, XO, 
represented ~ 20% of the combined XDH 
and XO activity at all oxygen concentrations.  
3.2. Inactivation of XOR active center by 
high oxygen 
To study the mechanism of inactivation of 
XOR in hyperoxia, the function of the main 
redox centers of XOR was evaluated. The 
function of the FAD center was apparently 
unaffected since the oxidation of NADH, 
which is dependent on the FAD center, was 
similar in sonicates of cells grown in 
normoxia, hypoxia, and hyperoxia.  
Incubation of purified XOR with hydrogen 
peroxide decreased XOR and DCPIP activity 
in parallel, suggesting that the molybdenum 
center of XOR lost its capacity to transfer 
electrons (III, Figure 6). 
 
 
 
Table 5. Summary of the effects of hypoxia (0.5-3% O2), hyperoxia (95% O2), 
and cobalt chloride on XOR in BEAS-2B and 293T cells (promoter experiments). 
Agent XOR 
 Activity Protein mRNA Promoter 
Hypoxia  ↑ ↔ ↔ ↔ 
Hyperoxia  ↓ ↔ - - 
Cobalt chloride ↔ - - - 
-, not analyzed; ↔, no change; ↑, increased; ↓, decreased 
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4. XOR expression and its clinical 
correlates in breast cancer (IV) 
4.1. XOR expression in breast cancer 
Forty-three percent of the 1262 tumors (n = 
543) studied showed strong XOR staining in 
the cytoplasm, similar to the staining in 
normal breast epithelial cells, and 50% (n = 
631) showed decreased XOR staining as 
compared to normal breast epithelium. Seven 
percent (n = 88) of the tumors showed 
minimal or no XOR immunostaining in the 
cytoplasm and were scored negative (Table 6 
and Figure 5). 
In 21% of the tumors XOR was strongly 
expressed in the nuclei, whereas 30% showed 
moderate, and 49% no nuclear XOR staining 
comparable to the nuclei of normal breast 
epithelial cells.  
To evaluate the heterogeneity of XOR 
expression, 20 sections of whole tumors were 
stained with the anti-XOR antibodies. 
Heterogeneity was minimal indicating that 
the staining results obtained from the tissue 
microarray cores are representative for the 
entire tumor. 
 
 
 
  
 
 
 
 
Table 6. Summary of XOR expression in the 1262 breast tumors studied. 
Localization          XOR Expression (%) 
 Strong Moderate Negative 
Cytoplasm 43 50 7 
Nucleus 21 30 49 
Figure 5. Immunohistochemical staining of XOR in breast cancer specimens on 
tissue microarray (A) as described in “Materials and Methods”. Examples of  
strong (B), moderate (C), and no (negative) (D) immunoreactivity in the 
cytoplasm. 
A B C D
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4.2. Association of decreased XOR 
expression with clinicopathological 
characteristics and outcome 
Decreased cytoplasmic XOR expression, as 
compared to the normal breast epithelium, 
was associated with clinicopathological 
variables such as large tumor size (P = 
0.043), large number of positive axillary 
lymph nodes (P = 0.022), and poor histologic 
grade of differentiation (P = 0.0002), but not 
with estrogen or progesterone receptor status, 
Ki-67 antigen, p53 protein, or ERBB2 
amplification (IV, Table 1).  
Patients with no cytoplasmic XOR 
expression had an unfavorable distant 
disease-free survival (DDFS) compared to 
those with strong or moderate XOR 
expression (P <0.0001; RR = 2.2) (Figure 6 
and IV, Table 2).  
In subgroup analysis, absence of cytoplasmic 
XOR expression predicted poorer survival in 
patients with node-negative disease, in 
patients with small tumor size, in patients 
with tumors of ductal type, and in hormone 
receptor positive and negative disease (IV, 
Table 2 and Figure 4).  
In a Cox multivariate analysis, absence of 
cytoplasmic XOR expression (P = 0.027; RR 
= 1.69), number of positive lymph nodes, 
tumor size, histological grade, and 
progesterone receptor status associated 
independently with prognosis (IV, Table 3A). 
In a subgroup of patients with node-negative 
breast cancer, absence of XOR also emerged 
as an independent prognostic factor (P = 
0.003; RR = 2.79) in addition to tumor size 
and histological grade (IV, Table 3B), 
whereas XOR expression did not retain 
independent prognostic significance among 
patients with node-positive disease (IV, 
Table 3C). 
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Figure 6. Distant disease-free survival of 
1262 patients with breast cancer according 
to XOR expression. —, moderate and strong 
(n = 1169); ----, negative (n = 93). P < 
0.0001 (logrank test for trend). 
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DISCUSSION 
 
1. Molecular forms of human XOR (I) 
1.1. XOR protein in tissue homogenates and 
serum 
In a study on the proteolysis of rat liver XOR 
by trypsin, the protein was partially cleaved 
into fragments of 85, 40, and 20 kDa, which 
did not dissociate from each other under 
nonreducing conditions (Amaya et al., 1990). 
Similar fragments or combinations of these 
could produce the pattern of bands we 
observed under reducing conditions. The 
differences in the number of XOR bands and 
sizes observed by us and others may also be 
due to artifacts in sample preparation or 
purification of the protein. For example, it 
was shown that after freezing and thawing of 
human liver bands of 150, 130, and 85 kDa 
appear in Western blots, whereas fresh liver 
XOR remains intact for up to 24 h with no 
signs of proteolysis (Saksela et al., 1999). 
Although we used fresh liver, and the 
samples were stored at -70°C in the presence 
of inhibitors of proteolysis, the homogenates 
showed multiple bands on Western blotting. 
It cannot be ruled out that the minor bands 
are artifacts due to freezing and thawing. 
To determine whether inactive XOR is 
present in human liver and intestine, XOR 
concentrations and activities were analyzed. 
The good correlation between XOR activity 
and XOR protein indicates that the relative 
amounts of inactive enzyme forms must be 
small and/or in constant proportion under 
varying conditions. The delay between death 
and sample processing may have affected the 
activity or immunoreactivity of XOR. 
However, since XOR activity and XOR 
protein correlated so well in the liver and 
intestine and during different developmental 
stages, it is unlikely that postmortem 
degradation affected the XOR antigen.  
In line with previous data showing 
undetectable XOR activity in normal human 
serum (Al-Khalidi and Chaglassian, 1965), 
we could not detect XOR protein in serum 
samples by Western blotting. We were thus 
unable to confirm a previous study reporting 
significant baseline concentrations of XOR in 
normal human serum (Adachi et al., 1993).  
1.2. Specificity of anti-XOR antiserum 
The anti-XOR antibodies revealed one major 
and several smaller bands upon Western 
blotting of purified XOR and liver 
homogenate. However, several 
considerations indicate that the protein used 
for immunization is, for all practical 
purposes, pure and that the antiserum 
produced is specific. XOR purified from 
human milk and used for immunization 
revealed only one major band which showed 
XOR activity after electrophoresis under 
non-denaturing conditions. The original 
antibody reacted with lactoferrin, but this 
reactivity was removed by absorption with 
lactoferrin. Major milk proteins such as β-
caseins and β-lactoglobulin did not react with 
the anti-XOR antibodies upon Western 
blotting.  
Moreover, when the main protein band of the 
purified milk preparation was eluted from the 
non-denaturing gel and partially sequenced, 
the sequence was identical with that reported 
for the rat XOR amino acid sequence 
(Amaya et al., 1990) but showed one amino 
acid difference from the human sequence 
(Ichida et al., 1993). Human serum did not 
show immunoreactivity on Western blotting 
or ELISA, showing that the anti-XOR 
antiserum does not show cross-reactivity 
with serum proteins. Finally, the fact that 
XOR activity and XOR protein in 
homogenates of liver and intestine correlate 
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so well, also suggests that the antiserum is 
specific for the protein. 
2. Localization of the XOR in normal 
human tissues (II) 
The results describing XOR localization in 
normal human tissues are essentially in 
accord with previous data, showing high 
XOR activities in the human liver, intestine, 
and mammary gland and no or minimal 
activity in other organs. What appears to be 
clear is that the enzyme is strictly regulated, 
its expression being limited to the epithelial 
cells of the intestine and mammary gland, 
hepatocytes, and capillary endothelial cells of 
some organs. 
2.1. Liver, intestine, and mammary gland 
We showed that, in the liver, XOR is 
strongly expressed in the periportal 
hepatocytes, whereas pericentral hepatocytes 
show clearly lower XOR expression. It is 
known that periportal and pericentral 
hepatocytes differ in the expression profile of 
many proteins (Jungermann, 1982). 
Hepatocytes receive diverse signals as a 
result of the gradients established due to 
passage of oxygen, substrates, and hormones 
through the liver, which may explain the 
patchy appearance of XOR in this organ. 
XOR activity has been localized to 
pericentral as well as periportal hepatocytes 
in postmortem human liver (Kooij et al., 
1992), whereas in another study zonation of 
the XOR distribution in the liver was absent 
(Moriwaki et al., 1993).  
In our study, XOR was strongly expressed in 
Kupffer cells of three of the nine liver 
samples examined. This could be a 
consequence of an upregulation of XOR by 
inflammatory mediators, which have the 
capacity to induce the protein at a 
transcriptional level (Kurosaki et al., 1995; 
Terao et al., 1992). Alternatively, XOR may 
have been taken up from the portal 
circulation by Kupffer cells, which are well 
known to be phagocytic.  
The strong XOR expression in goblet cells 
and enterocytes of the intestine in our study 
is in line with a previous report (Kooij et al., 
1992). The expression of XOR mRNA in the 
mouse duodenal epithelium (Kurosaki et al., 
1995) further supports our findings. 
However, in bovine intestinal epithelium 
XOR protein was not detected, whereas, in 
agreement with our results, capillary 
endothelial cells in the same organ were 
shown to express XOR (Jarasch et al., 1981). 
Our results showing intense XOR expression 
in the mammary epithelium during lactation 
is in accordance with studies showing strong 
XOR expression in bovine (Jarasch et al., 
1981) and mouse (McManaman et al., 2000; 
McManaman et al., 2002; Vorbach et al., 
2002) lactating mammary epithelium. Also in 
line with our study, increased XOR mRNA 
expression has been shown in the lactating 
mammary gland of mice as compared to the 
non-lactating breast (Kurosaki et al., 1996). 
Although we initially saw no staining of 
epithelial cells of the large ducts in non-
lactating breast tissue (II), modification of 
the method improved sensitivity and allowed 
detection of XOR in these cells (IV). 
2.2. Vascular endothelium 
In the present study, XOR was localized to 
the cytoplasm of the capillary endothelial 
cells of the intestine, mammary gland, 
skeletal muscle, and kidney. Previous data 
have also shown XOR expression in capillary 
endothelial cells of human skeletal muscle 
(Hellsten-Westing, 1993), as well as bovine 
mammary gland, intestine, and skeletal 
muscle (Jarasch et al., 1981). The low XOR 
mRNA concentrations previously detected in 
the human kidney (Saksela et al., 1998) can 
be explained by expression of the protein 
only in the vascular compartment of this 
organ. Such XOR-rich but relatively small 
subpopulations of endothelial cells could 
account for the minimal XOR activities 
detected in homogenates of human muscle 
(Hellsten-Westing, 1993) and kidney 
(Saksela et al., 1998).  
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Although vascular endothelial cells may 
produce XOR themselves, the possibility that 
circulating XOR adheres to or is taken up by 
the endothelium cannot be ruled out without 
data showing XOR mRNA expression in 
these cells. XOR activity and/or protein have 
been detected in serum after certain clinical 
conditions, such as intestinal ischemia 
(Terada et al., 1992a), liver transplantation 
(Pesonen et al., 1998), and viral hepatitis 
(Battelli et al., 1999). Once in the circulation, 
XOR has the capacity to bind to 
glycosaminoglycans on the surface of 
vascular endothelial cells (Adachi et al., 
1993; Houston et al., 1999), and 
subsequently to migrate to an intracellular 
compartment by endocytosis (Houston et al., 
1999).  
The vascular endothelium comprises a 
heterogenous cell population which is 
specialized, in response to genetic programs 
and micro-environmental signals, to take 
distinct roles in different vessels, tissues, and 
organs (Chi et al., 2003; Risau, 1995). This 
may be the reason for the selectivity of XOR 
expression in the capillary endothelium and 
arterioles of certain organs only. 
2.3. Heart and brain 
Trace amounts of XOR activity in the human 
heart (Wajner and Harkness, 1989) as well as 
mRNA in the human heart and brain (Saksela 
et al., 1998), have previously been detected. 
In contrast, the results in this study suggest 
that the human heart and brain parenchyma, 
and also the respective vascular 
compartments are devoid of XOR. This is of 
particular importance, since XOR has been 
suggested to have a role in the pathogenesis 
of cell damage following ischemia-
reperfusion of the heart (Das et al., 1987). 
For example, in the isolated postischemic rat 
heart, free radical generation was shown to 
be mediated by XOR (Xia and Zweier, 
1995).  However, most of the evidence is 
indirect and may at least partly be accounted 
for by pharmacological effects of allopurinol 
and its metabolite oxypurinol as free radical 
scavengers, not dependent of XOR inhibition 
(Moorhouse et al., 1987). Our results 
showing lack of XOR in heart and brain does 
not exclude the possibility that XOR is 
induced during pathological conditions. 
2.4. Methodological aspects 
Contradictory results in studies on XOR 
expression in human and animal organs may 
partly be explained by methodological 
problems. The specificity of the antibodies is 
crucial, and cross-reaction with the closely 
related AO protein (Terao et al., 1998) is a 
distinct possibility. Although we cannot 
strictly rule out this potential problem, it is 
rendered unlikely by the negative staining of 
the lung which is known to strongly express 
AO (Li Calzi et al., 1995).  
The specificity of our immunohistochemical 
findings was confirmed by staining the 
sections with and without the rabbit 
preimmune serum. Furthermore, the sections 
were stained with anti-XOR antibodies after 
absorption with purified XOR. Every 
immunohistochemical method has a limit of 
sensitivity, and positive staining indicates 
that this limit has been exceeded. A negative 
result does not rule out the presence of 
minute amounts of protein. 
The mRNA for XOR could not be detected 
using in situ hybridization, because the 
sensitivity of the assay apparently was not 
sufficient.  
3. Regulation of XOR by oxygen (III) 
3.1. Hypoxia 
Our results indicate that oxygen post-
translationally inactivates the molybdenum 
center of the XOR enzyme and that 
reactivation occurs in hypoxia. Previously, 
post-translational increase in XOR activity in 
hypoxic cells has been suggested to be a 
consequence of XO to XDH conversion 
(Wiezorek et al., 1994). In contrast, we could 
not show a change in the XDH to XO ratio 
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during hypoxia. However, our data are in line 
with those showing an increase in both 
enzyme forms (Hassoun et al., 1994; Terada 
et al., 1992b). In concordance with our 
findings, one study showed increased XOR 
activity but unchanged XOR protein and 
mRNA concentrations in anoxic bovine 
endothelial cells (Poss et al., 1996). 
However, others have concluded that XOR is 
transcriptionally regulated in hypoxia 
(Partridge et al., 1992; Terada et al., 1997). 
Based on our results, the suggestion that the 
increased XOR activity in hypoxia may be 
due to enhanced phosphorylation of the 
enzyme after 4 h of exposure in hypoxia 
(Kayyali et al., 2001) cannot be ruled out, 
although we could not detect activation of 
XOR during the same time frame. 
Lack of induction of XOR activity after 
treatment of cells with cobalt chloride 
suggests that the human XOR gene is not 
HIF-1α responsive, also supporting a role for 
post-translational rather than transcriptional 
regulation of human XOR in hypoxia, at least 
in the cell model we used. 
3.2. Hyperoxia 
Previous reports have suggested that XOR is 
transcriptionally downregulated in hyperoxia 
(Hassoun et al., 1994; Lanzillo et al., 1996). 
Our results indicating post-translational 
inactivation of XOR in hyperoxia do not 
support the mechanistic interpretation of 
these data, whereas they are in line with 
findings showing that reactive oxygen 
species inactivate the purified enzyme 
(Terada et al., 1991) and rat endothelial cell 
XOR (Terada et al., 1988). We suggest that 
XOR is inactivated during hyperoxia by 
reactive oxygen species, which convert the 
molybdenum center of the enzyme reversibly 
into an inactive desulfo-form. It is of interest 
to note that the free radical nitric oxide is 
also capable of reacting with the essential 
sulfur of the molybdenum center of XOR, to 
produce inactive desulfo XOR (Ichimori et 
al., 1999).  
We showed that the FAD center is unaffected 
in normoxic, hypoxic, and hyperoxic cells, 
but since we did not study the function of the 
Fe/S clusters which are potentially sensitive 
to oxygen (Beinert et al., 1997), we cannot 
rule out that these were also altered in the 
hyperoxic cells. 
Discrepancies in the published reports 
concerning the regulation of XOR by oxygen 
may reflect cell, tissue and/or species-
specific variations or differences in 
experimental conditions. We analyzed the 
regulation of XOR in hypoxia and hyperoxia 
in human cells, using transformed bronchial 
epithelial cells. Because of their anatomical 
localization, lung-derived cells are in direct 
contact with oxygen in vivo, while XOR 
operates under a much lower oxygen tension 
in most other organs (Ganong, 2003), 
including liver (Wolfle et al., 1983) and 
breast (Vaupel et al., 1991) tissue. Thus, it is 
possible that the results obtained cannot be 
extrapolated to other cell types and organs, or 
across species barriers. Nevertheless, it is 
worth pointing out that the so-called normal 
atmosphere in cell culture (21% O2) actually 
represents hyperoxia, and proteins other than 
XOR may also be sensitive to oxygen-
induced damage. 
4. XOR expression in breast cancer (IV) 
4.1. Expression and prognostic value of 
XOR in breast cancer 
We studied the expression of XOR in a large 
series of human breast cancer. The 
nationwide FinProg breast cancer database 
and the accompanying tumor tissue 
microarrays, containing specimens from 
approximately 1930 patients, were available 
for immunohistochemical analysis of XOR 
expression. Our results showed that the XOR 
expression in the cytoplasm of the epithelial 
cells was decreased in more than half of the 
breast tumors studied. This is in line with 
previous studies using animal tissues 
showing XOR activity to be lowered or 
absent in hepatomas (Ikegami et al., 1986) 
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and colon  tumors (Weber et al., 1978) as 
compared to corresponding normal tissue. 
Cytoplasmic XOR expression was relatively 
weakly associatiated with tumor size, nodal 
status, histologic grade, and no association 
was found between cytoplasmic XOR and 
hormone receptor status, proliferation rate as 
measured by Ki-67, p53 protein expression, 
or ERBB2 amplification. 
Lack of cytoplasmic XOR was not restricted 
to certain types of tumors, and XOR was also 
downregulated in early stage tumors, i.e. 
tumors of small size, node negative tumors, 
as well as p53 negative and estrogen receptor 
positive breast cancer, and those with low 
Ki-67 expression. This finding could indicate 
that downregulation of XOR is an early event 
in tumorigenesis, which is supported by the 
observation that XOR is also downregulated 
in ductal in situ carcinoma as compared to 
normal breast epithelium. 
Nuclear XOR expression has not been 
reported previously. XOR was expressed in a 
small fraction (5%) of the epithelial cell 
nuclei in a minority of the normal breast 
samples studied. In contrast, moderate to 
high nuclear XOR expression was found in 
approximately half of the breast cancers. 
Presence of XOR in cancer cell nuclei was 
associated with some adverse prognostic 
features, including increased COX-2 
expression, a large tumor size, and ERBB2 
amplification, but not with survival. The 
mechanism of translocation and the functions 
of nuclear XOR, if any, remain to be 
elucidated although unspecific binding of 
anti-XOR antibodies to the nucleus or 
nuclear membrane cannot be ruled out. 
The use of a tissue microarray technique 
(Kononen et al., 1998) enables evaluation of 
a large number of samples providing power 
to the statistical analysis. Decreased 
cytoplasmic XOR expression was found to 
be an independent prognostic factor in breast 
cancer, also in a subgroup of patients with 
small tumors and axillary node-negative 
disease. Thus, XOR could potentially emerge 
as a clinically useful marker in identifying 
patients with high risk of distant recurrence, 
even among those patients exhibiting an 
otherwise favorable prognostic profile 
according to established prognostic criteria 
e.g. patients with a small tumor size and 
lymph-node negative disease.  
4.2. Biological implications 
The results presented in (IV) will have to be 
validated in another series of breast cancer 
and a prospective study should be performed 
to confirm our results. Measurement of XOR 
activities and mRNA concentrations in breast 
cancer specimens will allow an interpretation 
of the present results based upon 
immunohistochemistry. It will also be 
important to elucidate the regulation of XOR 
during breast tumorigenesis and to clarify, 
whether the down-regulation of the purine 
catabolic XOR is associated with a 
corresponding up-regulation of purine 
anabolic enzymes in the same tumors. The 
role of other milk secretion-related proteins 
in breast cancer should also be analyzed, 
since these have been shown to be co-
localized with XOR during secretion of the 
milk fat droplet in lactating mammary 
epithelial cells (McManaman et al., 2002).  
Moreover, it will be interesting to clarify 
whether XOR is also down-regulated in other 
tumors derived from cells with strong normal 
(wild-type) expression of XOR, such as 
intestinal epithelial cells and hepatocytes. 
The concentration of a protein can potentially 
be regulated at several levels, particularly by 
transcriptional or posttranslational 
modification. Genetic alterations, such as 
allelic losses in the XOR chromosomal 
region, may also explain the diminished 
XOR expression. Such inactivating mutations 
include point mutations and deletions 
(Lengauer et al., 1998), leading to the loss of 
one allele detectable as loss of heterozygosity 
(LOH). Regions of the genome showing 
numerous LOH are expected to harbor tumor 
suppressor genes causing loss-of-function 
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effects. Also, “epigenetic” modifications 
such as hypermethylation of the promoter 
region should be taken into consideration 
(Herman and Baylin, 2003). To elucidate 
whether the diminished XOR expression is 
due to silencing of the XOR gene, LOH and 
comparative genomic hybridization analysis 
would be informative.  
It remains to be explored, whether tumors 
lacking XOR respond differently to 
pharmacological and hormonal therapy 
compared to those showing XOR expression, 
and if XOR expression status predicts 
response to a specific therapy. 
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CONCLUSIONS 
 
In this series of studies, the molecular forms of XOR, the relationship between XOR 
expression and XOR activity, and the expression of the protein in normal human tissues were 
elucidated. Furthermore, the regulation of the enzyme by oxygen in cultured human cells, and 
the expression of XOR and its potential prognostic significance in breast cancer were 
evaluated. Based on the results presented in this thesis, the main conclusions are: 
 
1.  Human XOR has a similar molecular size as other mammalian XOR enzymes. Since a 
linear correlation between XOR activity and XOR protein was found in the liver and 
intestine during development, the amount of inactive XOR apparently is small (I), 
whereas in human milk only approximately 20% of XOR appears active. 
 
2. In the normal human liver XOR is predominantly localized to periportal hepatocytes, 
and in the proximal intestine to enterocytes and goblet cells. The epithelial cells of the 
lactating mammary gland express XOR strongly but the epithelial cells of the normal 
mammary gland only moderately. Capillary endothelial cells in the intestine, 
mammary gland, and skeletal muscle show XOR immunoreactivity, whereas all cells 
in the heart, brain, and lung are below the detection limit (II). 
 
3. Hyperoxia, even under “normal” cell culture conditions, inactivates the molybdenum 
center of XOR posttranslationally, leading to loss of enzyme activity. The inactivation 
is reversed in hypoxia, resulting in apparent enzyme induction (III).  
 
4. The expression of XOR is decreased or undetectable in more than half of the cases of 
breast cancer, as compared to normal breast epithelium. Decreased expression of the 
protein in the cytoplasm is associated with several adverse prognostic features, but not 
with estrogen and progesterone receptor status, tumor suppressor protein p53, or 
proliferation associated Ki-67 antigen. Lack of XOR protein has independent 
prognostic value both in the entire patient series and in the subgroup of axillary-node 
negative disease (IV). 
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